Table 2.
Demographic and clinical characteristics of RA patients and HCs.
| RA | HCs | |
|---|---|---|
| n = 22 | n = 22 | |
| Age, years | 49.3 ± 8.5 | 36.72 ± 11.59 |
| Female, n (%) | 16 (72.7) | 16 (72.72) |
| ESR, mm/h | 18.9 ± 15 | |
| CRP, mg/dL | 1.01 ± 0.9 | |
| DAS28 score | 3.15 ± 1.3 | |
| HAQ score | 0.7 ± 0.6 | |
| ACPA positivity, n (%) | 12 (54.5) | |
| RF positivity, n (%) | 13 (59) | |
| Steroid use, n (%) | 12 (54.5) | |
| Steroid dose, mg/day | 1.58 ± 2.6 | |
| DMARDs use, % | 14 (63.6) | |
| TNFi use, % | 4 (3.3) | |
| Tocilizumab use, % | 7 (58.3) |
RA, rheumatoid arthritis; HCs, healthy controls; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS-28, disease activity score-28 joints; HAQ, health assessment questionnaire; ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; DMARDs, disease-modifying anti-rheumatic drugs; TNFi, tumor necrosis factor-alpha inhibitors.